display
Mainz / New York (dpa) - The Mainz company Biontech and its US partner Pfizer want to manufacture two billion doses of their corona vaccine this year under certain conditions.
That emerges from the documents from Biontech to the US Securities and Exchange Commission that became known on Monday.
So far, the companies had targeted 1.3 billion cans.
The condition for the desired increase in production are further improvements and enlargements in the previous locations as well as the availability of further suppliers and contractual partners for production, it says.
The target number of two billion doses is said to include the recently approved increase from five to six doses per ampoule.
Since Friday, more vaccine can be taken from the ampoules supplied by Biontech / Pfizer in the EU than before.
In order to be able to better use the vials with the Biontech vaccine, the EU Medicines Agency (EMA) allowed six instead of the previous five doses to be drawn from a Biontech / Pfizer vial.
The Federal Ministry of Health had already announced this as a possibility in December - due to an “overfilling” of the vials, six doses could be drawn from one with suitable syringes and needles.
According to the Biontech filings with the SEC, the two companies have so far agreed to ship a billion cans this year.
The production sites in Germany include Mainz and, from the end of February, Marburg in Hesse for Biontech and Puurs in Belgium, Kalamazoo, St. Louis and Andover (all USA) for Pfizer.
Biontech also announced that 32.9 million cans have been delivered so far (as of Sunday).
display
Biontech